Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (UK-Haplo)
A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies
Sponsor: Bloodwise
A PHASE2 clinical study on Acquired Bone Marrow Failure Syndromes and Acute Lymphoblastic Leukaemia, this trial is completed. The trial is conducted by Bloodwise and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2023 — Jun 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Oct 2021 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bloodwise
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .